News Release

GNI Signs Term Sheet to Acquire Hengshan Pharmaceuticals of Shanghai, China

• GNI Announces Donation to Earthquake Area of China
• China Patent and Trade Mark Office Grants Patent for RX50, a Drug Target Implicated in Human Cancers and Neurodegenerative Disorders